Press Release: AMCP Urges FDA to Issue Final Guidance on Biosimilar Interchangeability Standards and Provide Education on Substituting Interchangeable Products
AMCP CEO Blog: A new article in Health Affairs (http://bit.ly/2BQlgo9) highlights the challenges that many health plans and payers face as spending on pharmaceuticals continues to rise. The report, which looked at total health care spending at Harvard Pilgrim Health Care (HPHC) from 2011 and 2016, found that spending on pharmaceuticals had increased to a full 25% of all dollars spent.
The Academy of Managed Care Pharmacy (AMCP) supports off‐label use of FDA‐approved drugs when medically appropriate and necessary, but opposes government‐mandated coverage of specific pharmaceuticals, whether for FDA‐approved or off‐label uses.
The Academy of Managed Care Pharmacy (AMCP) is writing in strong support of the “Opioid Crisis Response Act”. The importance of this Act increases as the number of overdose deaths according to the CDC rise (72,000 overdose deaths in 2017).
The Academy of Managed Care Pharmacy (AMCP) is writing in strong support of the “Opioid Crisis Response Act”. The importance of this Act increases as the number of overdose deaths according to the CDC rise (72,000 overdose deaths in 2017).1 As you know, the Act will advance patient treatment and recovery initiatives, improve prevention of opioid addiction, protect communities, and bolster efforts to fight deadly illicit synthetic drugs like fentanyl.